High dose peptichemio in pretreated neuroblastoma.
The aim of this study was to evaluate the antitumor effect and toxicity of a single course of Peptichemio at high dose (450 mg/sq m) given to children with neuroblastoma resistant to first line treatment or at relapse. A total of 28 children were treated. Seven children showed partial response, 4 minor response, 8 had stable disease, and in 8 the tumor progressed. The principal toxic effect was myelosuppression. Hemorrhagic enteritis with liver failure and toxic death occurred in 1 patient. High dose Peptichemio can be administered with tolerable toxicity, inducing tumor regression in one third of previously treated patients.
Garaventa
A
A
Giannina Gaslini Children's Hospital, Genova, Italy.
De Bernardi
B
B
Cordero Di Montezemolo
L
L
Pastore
G
G
De Laurentis
C
C
Nardi
E
E
Casale
F
F
Mancini
A
A
Loiacono
G
G
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001772:Blood Cell Count; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008558:Melphalan / Q000031:analogs & derivatives*; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000188:drug therapy*; D010440:Peptichemio / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010440:Peptichemio; D008558:Melphalan